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Abstract Chronic Obstructive Pulmonary Disease (COPD) exacerbations play a central role in
the disease natural history of the disease, affecting its overall severity, decreasing pulmonary
function, worsening underlying co-morbidities, impairing quality of life (QoL) and leading to
severe morbidity and mortality. Therefore, identification and correct assessment of COPD exa-
cerbations is paramount, given it will strongly influence therapy success. For the identification
of exacerbations, several questionnaires exist, with varying degrees of complexity. However,
most questionnaires remain of limited clinical utility, and symptom scales seem to be more
useful in clinical practice. In the assessment of exacerbations, the type and degree of sever-
ity should be ascertained in order to define the management setting and optimize treatment
options. Still, a consensual and universal classification system to assess the severity and type
of an exacerbation is lacking, and there are no established criteria for less severely ill patients
not requiring hospital assessment. This might lead to under-reporting of minor to moderate
exacerbations, which has an impact on patients’ health status.
There is a clear unmet need to develop clinically useful questionnaires and a comprehensive
system to evaluate the severity of exacerbations that can be used in all settings, from primary
health care to general hospitals.
© 2017 Published by Elsevier España, S.L.U. on behalf of Sociedade Portuguesa de Pneumologia.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) exacerba-
tions play a central role in the natural history of the disease,
affecting its overall severity, decreasing pulmonary func-
tion, worsening underlying co-morbidities, impairing quality
of life (QoL) and leading to severe morbidity and mortality.1,2
Indeed, progression of COPD is highly determined by the
frequency and severity of exacerbations, deriving short
and long-term clinical consequences and potentially more
aggressive patterns of disease.1
Exacerbations vary greatly in terms of severity at clinical
presentation, etiological factors and response to treatment,
reflecting the heterogeneity of the disease.
The definition of COPD exacerbation has evolved over
time, from more specific to broader definitions, based on
symptoms or event-based, according to treatment needed
or to health care resources used.3 Lack of expert consensus
may be responsible for this shift toward generic definitions.
The large clinical and physiopathological heterogeneity of
COPD exacerbations between patients, and within the same
patient, leads to the absence of an evidence-based or gen-
erally agreed definition.3
As such, a widely accepted definition is indeed of
paramount importance, as it would determine the rate of
reported exacerbations, facilitating a more precise clinical
and research approach to the issue.
Definition of exacerbation
Despite growing evidence supporting the importance of
COPD exacerbations in disease burden and the implica-
tions on its natural history, many remain unreported and
untreated by health care professionals.3,4 It is known that
unreported exacerbations have an impact on the health sta-
tus of patients, although they are usually shorter in duration
and with lower severity.2 The early recognition of exacerba-
tions allows for early therapy, leading to faster recovery,
better QoL and reduced risk of hospitalization.5
The choice of a definition for exacerbation deter-
mines the rate of the observed events, permitting better
treatment. There are numerous definitions of COPD exacer-
bations, of which we will only mention a few: (a) a worsening
of at least one key symptom (dyspnea, sputum amount, spu-
tum color) for at least 2 consecutive days6; (b) a sudden
symptomatic worsening that is beyond daily variability7; (c)
an unscheduled or emergency visit due to worsening of COPD
or a course of oral steroids8; (d) the use of antibiotics,
steroids, or both or hospital admission related to worsen-
ing respiratory symptoms9; (e) a sustained acute/subacute
worsening of the severity or frequency of symptoms such
as dyspnea, cough or sputum production, with increased
QoL impairment, lasting at least 3 days, which prompts the
patient to seek medical attention or leads to a change in
medication.1
Generally, most definitions include one of the fol-
lowing criteria: need to use health care resources; the
use of additional therapy (antibiotics or corticosteroids);
deterioration of two major symptoms or one major symp-
tom and two minor symptoms (Anthonisen criteria; major
symptoms: dyspnea, sputum volume, sputum purulence;
minor symptoms: cough, wheezing, sore throat, coryzal
symptoms)10; deterioration of one major symptom; change
in two or more symptoms; or a combination of the
previous criteria.11 Centralizing the definition in the occur-
rence of major symptoms has the risk of not identifying
exacerbations with need of hospitalization, as well as
the total number of exacerbations. On the other hand,
including minor symptoms will increase the number of
patients treated, and decrease the number of patients with
need of in-hospital treatment.11
Less usually, definitions are event-based, taking into
account the necessity to search health care resources.
However, these definitions tend to fail to capture all exacer-
bations, underestimating true rates by 50%, as patients do
not always seek medical attention.6 Moreover, they depend
on the organization of each specific health system and
resources.
Currently, the Global Strategy for the Diagnosis, Manage-
ment and Prevention of COPD, Global Initiative for Chronic
Obstructive Lung Disease (GOLD) 2017 defines an exacer-
bation as an acute worsening of respiratory symptoms that
results in additional therapy.2
The authors acknowledge the difficulty in establishing a
consensual definition of COPD exacerbation and favor the
definition provided by GOLD 20172 after excluding worsening
of comorbidities. It has the advantage of increasing the num-
ber of exacerbations detected, allowing for early treatment
even if at the expense of over-diagnosis.
Types of exacerbations
COPD is a highly heterogeneous disease, during both stable
and acute states, with an extensive range of clinical presen-
tations, and prevention of exacerbations is usually based on
the phenotype of stable disease.
Different COPD exacerbations phenotypes have been
identified, with specific inflammatory profiles and biomark-
ers, and there is some evidence that these profiles show
diverse clinical patterns in terms of prognosis and response
to treatment. Therefore, identifying these phenotypes and
developing a phenotype-specific treatment approach and
prevention strategies has the potential to improve out-
comes.
Etiologically, exacerbations of COPD can be precip-
itated by several factors. The most common causes
appear to be respiratory tract infections, either
viral-predominant, bacteria-predominant, eosinophil-
predominant or mixed.2,3,7,12--16 Exacerbations may also be
pauci-inflammatory,16 or mediated by a decrease in mean
ambient temperatures,17 air pollution and comorbidities.2,7
Poor compliance to maintenance therapy has also been
shown to lead to exacerbations.2,18,19 However, in one-
third of severe COPD exacerbations the cause cannot be
identified.2,7
Some authors report that approximately 70% of exacer-
bations may have viral origin,7 whilst others report that
bacterial infections account for more than 50% of the acute
episodes.14,15 Bacterial infection is usually mediated by
Haemophilus influenza, Moraxella catarrhalis, Streptococ-
cus pneumonia, Staphylococcus aureus and Pseudomonas
44 A.S. Oliveira et al.
aeruginosa.16 The occurrence of mixed viral--bacterial infec-
tions has also been confirmed in several studies.7,12--14
At least 50% of patients have bacteria in their lower
airways during COPD exacerbations, but a significant pro-
portion of these patients also have bacteria colonizing the
respiratory tract in the stable phase of the disease.20 There
is some indication that the bacterial burden increases dur-
ing some exacerbations and that the acquisition of new
bacterial strains is associated with exacerbation episodes.2
The probability of attributing an exacerbation to a bacte-
rial infection is established by the Anthonisen criteria, and
is associated with the following: increase in the degree of
dyspnea, increase in sputum production and increase in spu-
tum purulence.7 Bacteria-associated exacerbations can also
be identified by biomarkers such as sputum IL-1 (sensitivity
of 90% and a specificity of 80%) and serum C-reactive protein
(CRP) (sensitivity of 60% and a specificity of 70%).16 As for
viral predominant exacerbations, the same authors describe
CXCL10 as the best biomarker, with a sensitivity of 75% and
a specificity of 65%.16
There is also a subset of patients in whom an eosinophilic
airway inflammation predominates, which is associated
with higher all-cause mortality.16 These patients mani-
fest increased eosinophilic peripheral and sputum counts,
and may represent the subgroup amenable to systemic
corticosteroids-based treatment.16
Less frequently, patients reveal a pauci-inflammatory
pattern, with limited changes in the inflammatory profile,
as well as low sputum mediator concentrations related to
bacterial, viral or eosinophilic etiologies.16
Comorbidities can act as etiological factors, triggering
exacerbations but also mimicking them.7 These conditions
include pneumonia, pulmonary embolism, congestive heart
failure, cardiac arrhythmia, pneumothorax, and pleural
effusion, need to be considered, and treated if present.2,19
A diagnosis of certainty or probability must be made, a
differential diagnosis must be performed and an etiologic
diagnosis must be established.7 Etiology can be partially
determined from the diary card and this emphasizes the
importance of careful monitoring of patients to detect
exacerbations.3
Identification of exacerbations
The early identification of exacerbations is of utmost impor-
tance since these events have a great impact on patients’
morbidity, mortality and quality of life.2,6,7,21 Less than one
third of exacerbations are estimated to be reported, with
the number of symptoms at onset being the most impor-
tant predictor of reporting an exacerbation,6 meaning if
more symptoms are present it is more likely that the patient
reports an exacerbation. Therefore, a specific questionnaire
that captures the onset of an exacerbation is necessary.
Questionnaires can be self-administered, based on self-
perception, symptoms and quality of life records, and
can detect significant clinical changes.22--26 Scales that are
symptom-based seem to be better suited to support clinical
decisions.27--29
Several questionnaires exist for the assessment of both
symptoms and quality of life in COPD patients, namely
the modified Medical Research Council (mMRC), the Clinical
COPD Questionnaire (CCQ), the COPD Assessment Test (CAT),
and the health-related quality of life St. George’s Respira-
tory Questionnaire (SGRQ).2,6
Questionnaires such as the mMRC, CCQ and CAT may
be helpful in the evaluation of exacerbations.1 Although a
specific CAT score increase, suggesting the presence of an
exacerbation, has not been validated,7 two studies have
shown that this questionnaire is sensitive to the change
in health status associated with COPD exacerbations,30,31
and that changes in CAT correlate well with changes in
SGRQ.31 CAT can indeed be used to predict COPD exa-
cerbations, health status deterioration, depression and
mortality.27 Another study proposes that, in primary care,
a shortened and more specific version of the CCQ could
be used to screen for exacerbations by measuring dys-
pnea, coughing and phlegm32 production. CCQ was found
to be a promising low burden method to detect unreported
exacerbations, in a multicenter prospective study.24 Daily
symptom diaries (eDiary) have also been used both in clinical
practice and in the research setting to identify and pre-
dict symptoms worsening. In the FLAME and SPARK studies
exacerbations have been captured using this tool.33,34 One
study using smartphone-based collection of COPD symptom
diaries enabled near-complete identification of exacerba-
tions at inception.35 Regarding the EXAcerbations of Chronic
pulmonary disease Tool (EXACT), it has been found that exa-
cerbations fully met the criteria for an EXACT event, in a
patient-report outcome diary, however this is more useful
for research than for clinical practice.23
It is recognized that further research is needed to identify
new features associated with symptoms and physiological
signals that may enable the early detection of deteriorations
in COPD.21 As most questionnaires remain of limited clinical
utility, the panel recommends using symptom scales as they
seem to be more valuable.
Severity and referral
The degree of exacerbation severity should be ascertained in
order to define the management setting.7 However, a con-
sensual and universal severity classification system for an
exacerbation is still lacking1 and there are no established
criteria for the assessment of severity in less severely ill
patients, not requiring hospital care.3
The American Thoracic Society/European Respiratory
Society severity scale can be used in the assessment of exa-
cerbations: level I (mild) patient is treated at home; level
II (moderate) patient requires hospitalization; and level III
(severe) exacerbation leads to respiratory failure, one of
the indications for intensive care.36 Other severity scales
exist, e.g., in mild exacerbations the patient is treated
at home, in moderate exacerbations the patient is medi-
cated with systemic corticosteroids, antibiotics or both, and
severe exacerbations require hospital admission or emer-
gency treatment.34 Yawn et al. propose an algorithm for the
management of exacerbations of different severities.36
The GOLD 2017 recommendations classify exacerbations
as mild -- treated with short acting bronchodilators only,
SABDs, moderate -- treated with SABDs plus antibiotics
and/or oral corticosteroids, severe -- patient requires hospi-
talization or visits the emergency room; these exacerbations
Identification and assessment of COPD exacerbations 45
may also be associated with acute respiratory failure -- and
very severe if they require admission to an Intensive Care
Unit (ICU).2 In 2013, Trigueros Carrero proposed a more com-
plex classification, grading exacerbations in mild, moderate,
severe and very severe, based on past medical history, his-
tory of present illness, clinical examination features and
severity of stable COPD.7 The panel considers that despite
being an interesting classification, comprising a larger com-
plexity of characteristics, it has limited prognostic value and
has not been validated for clinical use.
Potential indications for hospitalization assessment focus
on acute respiratory failure, severe symptoms such as sud-
den worsening of resting dyspnea, high respiratory rate,
decreased oxygen saturation, confusion and drowsiness,
failure to respond to initial medical treatment, presence of
serious comorbidities and insufficient home support.2 The
NHS protocol for management of COPD exacerbations in pri-
mary care also recommends referral to a Hospital in severe
exacerbations as patients need to be assessed by a specialist
in adequate settings.37 One study proposes that CAT pro-
vides a reliable score, with scores increasing at the time of
exacerbation and reflecting its severity.38
For patients who are hospitalized, the GOLD 2017 guide-
lines propose to differentiate those with and without
respiratory failure, and, among the former, between those
who have and do not have a life-threatening disease.2 It is a
simple classification, however of limited operational utility,
and it is the panel’s opinion that it does not help in clinical
decision making.
The panel recommends that a useful classification should
include features of the baseline disease characteristics as
well as characteristics of clinical worsening.
Management
Acute phase
The optimal management should take into account not
only the severity but also the type of exacerbation, in
order to select the appropriate treatment and to improve
outcomes. A standardized color chart is available to differ-
entiate between bacterial and non-bacterial exacerbations
by sputum color, which separates exacerbations that can be
safely managed without an antibiotic from those requiring
an antibiotic.3,7,12 This color chart has a 94.4% sensitivity and
a 77.0% specificity.39 Sputum color can be reproducibly clas-
sified by trained technicians using this standardized color
chart.
An exacerbation associated with purulent sputum pro-
duction will be associated with a large bacterial load,
and should be responsive to appropriate antibiotic treat-
ment, while an exacerbation associated with a common
cold or with upper respiratory tract symptoms is likely to
be viral in origin.3,7,12 Exacerbations associated with viral
infections are related to more airway inflammation than
non-viral ones, and thus, it would be expected that these
exacerbations may be more responsive to therapy with anti-
inflammatory agents.3 CRP levels have been reported to be
higher in bacterial infections, and may therefore be a useful
biomarker for the management of exacerbations in patients
with severe disease.14 Procalcitonin has been extensively
evaluated as a biomarker for bacterial acute exacerbations
of COPD and it has been shown that it can be safely used to
reduce inappropriate antibiotics in acute exacerbations of
COPD.40 A high level of eosinophils is a biomarker of exacer-
bations that respond better to corticosteroid therapy.16
Determining exacerbation frequency is important for
treatment success with empirical antibiotic selection,41
since different bacterial etiology has been observed depend-
ing on the number of annual episodes.13,41
Management of acute exacerbations should be based on
their severity.
Prevention of future exacerbations
Strategies for the prevention of exacerbations include non-
pharmacological and pharmacological approaches. Smoking
cessation, influenza and pneumococcal vaccination, early
pulmonary rehabilitation, and encouragement of patients to
maintain physical activity are proven strategies. Regarding
pharmacological treatment, LABA + LAMA are the preferred
option for symptomatic patients with ICS, macrolides or
phosphodiesterase inhibitors reserved for specific patient
sub-populations.2,4,36
A change of ≤4 points in the CAT score at discharge
compared to that obtained at hospital admission due to a
severe exacerbation predicts therapeutic failure, namely a
new exacerbation, hospital re-admission or death in the sub-
sequent three months.42 CAT seems to be a simple tool to
assist in the identification of patients at increased risk of
further exacerbations.22 Viral exacerbations do not seem to
be associated with a higher rate of successive exacerbations
or mortality during the following year.43
Conclusions
The identification and correct assessment of COPD exacer-
bations is vital, given that it will strongly influence therapy
success and impact on patients’ morbidity, mortality and
quality of life. Currently, there is a lack of clinically use-
ful questionnaires and a widespread classification system
to assess severity of exacerbations that can be used in all
settings, which might not only lead to under-reporting of
less severe exacerbations but may also hamper their proper
management.
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